FDA
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
-
-
-
-
-
-
-
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals finds Babesia in 24% of chronic fatigue patients
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals reports first patient clears babesia infection
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals estimates $245M annual market for babesiosis drug
-
327,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

